Back to Awarded Treatment Trials
Awarded Trial: 09T-1281
Grant ID
09T-1281
Illness
Schizophrenia
Primary Drug/Intervention
Omega-3 fatty acids (EPA 2g/day and DHA 1g/day)
Primary Dosage
3 g/day
Secondary Drug Intervention
Alpha-lipoic acid
Secondary Dosage
300 mg/day
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Emsley
Sample Size
80
Duration of Study Period for Each Subject
3 years
Outcome Measurements
N/A
Results
Patients who were successfully treated for 2-3 years after a first-episode of schizophrenia, schizo-affective or schizophreniform disorder were randomized to receive omega-3 polyunsaturated fatty acids (ù-3 PUFAs) and alpha-lipoic acid (á-LA) or placebo. Recruitment was terminated prematurely due to high relapse rates in both treatment groups. Thirty-three patients were randomized; of these, 19/21 receiving treatment drug relapsed, and 9/12 receiving placebo relapsed. There was no significant difference between the mean time to relapse and relapse symptom severity between the two groups.
Publication
N/A
Link
N/A
PI Name
Robin Emsley
Degree
MD
Center
Psychiatry
Institution
University of Stellenbosch
Address
PO Box 19063, Tygerberg
City or Town
Cape Town
State or Province
Western Cape
Zip or Postal Code
7505
Country
South Africa
Email Address
rae@sun.ac.za